

**Supplementary table 1. STI status by tenofovir diphosphate concentrations at week 26 and week 52 among PrEP acceptors**

	Overall	Low TFV-DP concentration (<700 fmol/punch)	High TFV-DP concentration (>=700fmol/punch)
<b>Week 26</b>			
CT/GC positive	142/363 (39.1%)	123/287 (42.9%)	19/76 (25.0%)
CT positive	114/363 (31.4%)	102/287 (35.5%)	12/76 (15.8%)
GC positive	44/363 (12.1%)	35/287 (12.2%)	9/76 (11.8%)
<b>Week 52</b>			
CT/GC positive	142/347 (40.9%)	123/317 (38.8%)	19/30 (63.3%)
CT positive	114/347 (32.9%)	102/317 (32.2%)	12/30 (40.0%)
GC positive	44/347 (12.7%)	35/317 (11.0%)	9/30 (30.0%)

CT: *C. trachomatis*; GC: *N. gonorrhoeae*; TFV-DP: tenofovir diphosphate

Supplementary table 2. Baseline characteristics, by site

	<b>Overall (N=451)</b>	<b>Cape Town (n=141)</b>	<b>Johannesburg (N=162)</b>	<b>Harare (N=148)</b>	<b>p-values</b>
<b>Age</b>					<b>&lt;0.0001</b>
Median (IQR)	21 (19, 22)	19 (18, 21)	22 (20, 24)	21 (20, 23)	
<b>Highest Level of Education</b>					<b>&lt;0.0001</b>
Primary school or less	9(2%)	1 (0%)	1 (0%)	7 (5%)	
Secondary school, not complete	160 (35%)	80 (57%)	27 (17%)	53 (36%)	
Secondary school, complete	228 (51%)	46 (33%)	96 (59%)	86 (58%)	
Post-secondary school	54 (12%)	14 (10%)	38 (23%)	2 (1%)	
<b>Ever Dropped out of School</b>	128 (28%)	45 (32%)	24 (15%)	59 (40%)	<b>&lt;0.0001</b>
<b>Regular place to stay</b>	404 (90%)	129 (92%)	140 (87%)	135 (91%)	<b>0.038</b>
<b>Live with</b>					<b>&lt;0.0001</b>
Living with parents or siblings	258 (57%)	129 (91%)	78 (48%)	51 (34%)	
Living with partner	98 (22%)	7 (5%)	24 (15%)	67 (45%)	
Living with someone else	95 (21%)	5 (4%)	60 (37%)	30 (20%)	
<b>Partner age difference (n=349)</b>					<b>&lt;0.0001</b>
Less than 5 years	200 (57%)	44 (37%)	81 (64%)	75 (73%)	
>=5 and <10 years	115 (33%)	52 (43%)	37 (29%)	26 (25%)	
>=10 years	34 (10%)	24 (20%)	8 (6%)	2 (2%)	
<b>Partner has other partners, past 3 mo. (n=379)</b>					<b>&lt;0.0001</b>
No	76 (20%)	26 (23%)	40 (28%)	10 (8%)	
Yes	121 (32%)	26 (23%)	37 (26%)	58 (47%)	
Don't know or prefer not to answer	182 (48%)	62 (55%)	64 (45%)	56 (46%)	

	<b>Overall (N=451)</b>	<b>Cape Town (n=141)</b>	<b>Johannesburg (N=162)</b>	<b>Harare (N=148)</b>	<b>p-values</b>
<b>Partner has made you feel afraid, unsafe or in danger – past year</b>	90/449 (20%)	23/140 (16%)	18/161 (11%)	49/148 (33%)	<b>&lt;0.0001</b>
<b>Ever pregnant (n=449)</b>	238 (53%)	46 (33%)	76 (47%)	116 (78%)	<b>&lt;0.0001</b>
<b>Contraceptive method at baseline</b>					<b>&lt;0.0001</b>
Injectable Contraceptives	191 (42%)	88 (62%)	76 (47%)	27 (18%)	
Implants	104 (23%)	25 (18%)	11 (7%)	68 (46%)	
IUD or Sterilization	5 (1%)	2 (1%)	1 (1%)	2 (0%)	
Oral Contraceptives	54 (12%)	9 (6%)	11 (7%)	34 (23%)	
Condoms, natural methods or none	79 (22%)	17 (12%)	63 (38%)	17 (11%)	
<b>Transactional sex Past month</b>	101/451 (22%)	30/141 (21%)	17/162 (10%)	54/148 (36%)	<b>&lt;0.0001</b>
<b>No. vaginal sex episodes, past mo. (n=359)</b>					<b>&lt;0.0001</b>
Median (IQR)	4 (2, 8)	4 (3, 5)	3 (2, 7)	6 (3, 17)	
<b>Condom use at last sex (n=352)</b>	140 (40%)	46 (42%)	50 (38%)	46 (42%)	
<b>Drug use before/during sex, past mo. (n=449)</b>	23 (5%)	2 (1%)	7 (4%)	14 (9%)	<b>0.0079</b>
<b>Anal Sex Past month</b>					<b>0.0507</b>
Yes	68 (15%)	30/141 (21%)	18/162 (11%)	20/148 (14%)	
Prefer Not to Answer	136 (30%)	36/141 (26%)	47/162 (29%)	53/148 (36%)	
No	247 (55%)	75/141 (53%)	97/162 (60%)	75/148 (51%)	
<b>High self-perceived risk of HIV (n=449)</b>	34 (8%)	5 (4%)	1 (1%)	28 (19%)	<b>&lt;0.0001</b>
<b>Modified voice score</b>					<b>0.0002</b>
Median (IQR)	7 (5, 7)	7 (6, 7)	7 (6, 7)	6 (5, 7)	

IQR: interquartile range

**Supplementary figure 1. Prevalence of curable STIs, by visit**